Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter study to assess the antitumor effect and safety of fludarabine phosphate tablet (SH T 586) in combination with rituximab administered in 6 treatment cycles (1 treatment cycle: rituximab 375 mg/m2 iv on day 1 along with 5-consecutive day oral dosing of SH T 586 40 mg/m2/day from day 1 to day 5, followed by an observation period of 23 days) in patients with indolent lymphoma.

X
Trial Profile

A multicenter study to assess the antitumor effect and safety of fludarabine phosphate tablet (SH T 586) in combination with rituximab administered in 6 treatment cycles (1 treatment cycle: rituximab 375 mg/m2 iv on day 1 along with 5-consecutive day oral dosing of SH T 586 40 mg/m2/day from day 1 to day 5, followed by an observation period of 23 days) in patients with indolent lymphoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fludarabine (Primary) ; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Bayer; Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 07 Jul 2009 Actual patient number (21) added as reported by ClinicalTrials.gov.
    • 17 Nov 2008 Actual end date added; patient inclusions and exclusions updated.
    • 17 Nov 2008 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top